ThabitH, HovorkaR: Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia, 2016. [Epub ahead of print]; DOI: 10.1007/s00125-016-4022-4.
2.
ThabitH, TauschmannM, AllenJM, et al.: Home use of an artificial beta cell in type 1 diabetes. N Engl J Med, 2015; 373:2129–2140.
3.
KropffJ, Del FaveroS, PlaceJ, et al.: 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol, 2015; 3:939–947.
4.
HaidarA, LegaultL, MessierV, et al.: Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol, 2015; 3:17–26.
5.
HaidarA, SmaouiMR, LegaultL, Rabasa-LhoretR: The role of glucagon in the artificial pancreas. Lancet Diabetes Endocrinol, 2016; 4:476–479.
6.
RussellSJ, El-KhatibFH, SinhaM, et al.: Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med, 2014; 371:313–325.
7.
WeinzimerSA, SteilGM, SwanKL, et al.: Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care, 2008; 31:934–939.
8.
CameronF, NiemeyerG, WilsonDM, et al.: Inpatient trial of an artificial pancreas based on multiple model probabilistic predictive control with repeated large unannounced meals. Diabetes Technol Ther, 2014; 16:728–734.
9.
GingrasV, HaidarA, MesslerA, et al.: A simplified semiquantitative meal bolus strategy combined with single and dual-hormone closed-loop delivery in patients with type 1 diabetes: a pilot study. Diabetes Technol Ther, 2016; 18:464–471.
10.
HaidarA, ElleriD, KumareswaranK, et al.: Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes. Diabetes Care, 2013; 36:e173–e174.
11.
BellKJ, SmartCE, SteilGM, et al.: Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care, 2015; 38:1008–1015.
12.
JacobsPG, El YoussefJ, CastleJ, et al.: Automated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies. IEEE Trans Biomed Eng, 2014; 61:2569–2581.
13.
HaidarA, FaridD, St-YvesA, et al.: Post-breakfast closed-loop glucose control is improved when accompanied with carbohydrate-matching bolus compared to weight-dependent bolus. Diabetes Metab, 2014; 40:211–214.
14.
El YoussefJ, CastleJR, BakhtianiPA, et al.: Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care, 2014; 37:3054–3060.
15.
LyTT, RoyA, GrosmanB, et al.: Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care, 2015; 38:1205–1211.
16.
TrevittS, SimpsonS, WoodA: Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development?. J Diabetes Sci Technol, 2015. [Epub ahead of print]; DOI: 10.1177/1932296815617968.
17.
NewswangerB, AmmonsS, PhadnisN, et al.: Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Technol, 2015; 9:24–33.
18.
HeiseT, HövelmannU, BrøndstedL, et al.: Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab, 2015; 17:682–688.
19.
SherrJL, PatelNS, MichaudCI, et al.: Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide. Diabetes Care, 2016; 39:1127–1134.
20.
BasuR, JohnsonML, KudvaYC, BasuA: Exercise, hypoglycemia, and type 1 diabetes. Diabetes Technol Ther, 2014; 16:331–337.
21.
DaveyRJ, HoweW, ParamalingamN, et al.: The effect of midday moderate-intensity exercise on postexercise hypoglycemia risk in individuals with type 1 diabetes. J Clin Endocrinol Metab, 2013; 98:2908–2914.
22.
RamnananCJ, EdgertonDS, KraftG, CherringtonAD: Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab, 2011; 13(Suppl 1):118–125.
23.
JacobsPG, El YoussefJ, ReddyR, et al.: Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab, 2016. [Epub ahead of print]; DOI: 10.1111/dom.12707.
24.
BischofMG, KrssakM, KrebsM, et al.: Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes, 2001; 50:392–398.
25.
RanjanA, SteineckI, SchmidtS, et al.: Low-carbohydrate diet reduces the effect of glucagon on glucose recovery during mild hypoglycemia in patients with type 1 diabetes. In: American Diabetes Association 76th Scientific Session. June 10–14, 2016; New Orleans, Louisiana, USA; 136-LB 2016.
26.
RussellSJ, HillardMA, BalliroC, et al.: Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol, 2016; 4:233–243.
27.
MassaraF, MartelliS, CaglieroE, et al.: Influence of glucagon on plasma levels of potassium in man. Diabetologia, 1980; 19:414–417.
28.
LefebvrePJ, LuyckxAS. Effect of insulin on glucagon enhanced lipolysis in vitro. Diabetologia, 1969; 5:195–197.
29.
ParmleyWW, GlickG, SonnenblickEH. Cardiovascular effects of glucagon in man. N Engl J Med, 1968; 279:12–17.
30.
CastleJR, YoussefJE, BraniganD, et al.: Comparative pharmacokinetic/pharmacodynamic study of liquid stable glucagon versus lyophilized glucagon in type 1 diabetes subjects. J Diabetes Sci Technol, 2016. [Epub ahead of print]; DOI: 10.1177/1932296816653141.
